Johnson & Johnson Reports Q1 2025 Results
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Apr 15, 2025--
Johnson & Johnson (NYSE: JNJ) today announced results for first-quarter 2025. 'The power of Johnson & Johnson's uniquely diversified portfolio was on full display this quarter, with strong operational sales growth reinforcing our confidence in 2025 guidance,' said Joaquin Duato, Chairman and Chief Executive Officer, Johnson & Johnson. 'During the quarter, we fortified our position as an innovation powerhouse with major advancements across our pipeline, including TREMFYA in IBD, RYBREVANT plus LAZCLUZE in non-small-cell lung cancer, and OTTAVA, our soft tissue surgical robotic system, and further enhanced our leading neuroscience portfolio with the completion of the Intra-Cellular Therapies acquisition.'
Overall financial results
Regional sales results
Segment sales results
First-Quarter 2025 segment commentary:
Operational sales* reflected below excludes the impact of translational currency.
Innovative Medicine
Innovative Medicine worldwide operational sales grew 4.2%* driven primarily by DARZALEX, CARVYKTI, ERLEADA, and RYBREVANT/LAZCLUZE in Oncology, TREMFYA and SIMPONI/SIMPONI ARIA in Immunology, SPRAVATO in Neuroscience, and XARELTO in Cardiovascular/Metabolism/Other. Growth was partially offset by an approximate (810) basis points impact from STELARA in Immunology.
MedTech
MedTech worldwide operational sales grew 4.1%*, with net acquisitions and divestitures positively impacting growth by 2.8%. Growth was driven primarily by Abiomed in Cardiovascular and wound closure products in General Surgery. Growth was partially offset by Spine, Sports & Other in Orthopaedics.
Full-year 2025 guidance:
Johnson & Johnson does not provide GAAP financial measures on a forward-looking basis because the company is unable to predict with reasonable certainty the ultimate outcome of legal proceedings, unusual gains and losses, acquisition-related expenses, and purchase accounting fair value adjustments without unreasonable effort. These items are uncertain, depend on various factors, and could be material to Johnson & Johnson's results computed in accordance with GAAP.
Other modeling considerations will be provided on the webcast.
Notable announcements in the quarter:
The information contained in this section should be read together with Johnson & Johnson's other disclosures filed with the Securities and Exchange Commission, including its Current Reports on Form 8-K, Quarterly Reports on Form 10-Q and Annual Reports on Form 10-K. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. The reader is also encouraged to review all other news releases and information available in the Investor Relations section of the company's website at News Releases, as well as Innovative Medicine News Center, MedTech News & Events, and www.factsabouttalc.com.
Webcast information:
Johnson & Johnson will conduct a conference call with investors to discuss this earnings release today at 8:30 a.m., Eastern Time. A simultaneous webcast of the call for investors and other interested parties may be accessed by visiting the Johnson & Johnson website. A replay and podcast will be available approximately two hours after the live webcast in the Investor Relations section of the company's website at events-and-presentations.
About Johnson & Johnson:
At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity. Learn more at www.jnj.com.
Non-GAAP financial measures:
* 'Operational sales growth' excluding the impact of translational currency, 'adjusted operational sales growth' excluding the net impact of acquisitions and divestitures and translational currency, as well as 'adjusted net earnings', 'adjusted diluted earnings per share' and 'adjusted operational diluted earnings per share' excluding after-tax intangible amortization expense and special items, are non-GAAP financial measures and should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures. Except for guidance measures, reconciliations of these non-GAAP financial measures to the most directly comparable GAAP financial measures can be found in the accompanying financial schedules of the earnings release and the Investor Relations section of the company's website at quarterly results.
Copies of the financial schedules accompanying this earnings release are available on the company's website at quarterly results. These schedules include supplementary sales data, a condensed consolidated statement of earnings, reconciliations of non-GAAP financial measures, and sales of key products/franchises. Additional information on Johnson & Johnson, including adjusted income before tax by segment, an Innovative Medicine pipeline of selected compounds in late stage development and a copy of today's earnings call presentation can also be found in the Investor Relations section of the company's website at quarterly results.
Note to investors concerning forward-looking statements:
This press release contains 'forward-looking statements' as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things: future operating and financial performance, product development, and market position and business strategy. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: economic factors, such as interest rate and currency exchange rate fluctuations or changes to applicable laws and regulations; competition, including technological advances, new products and patents attained by competitors; challenges inherent in new product research and development, including uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success for new and existing products; challenges to patents; the impact of patent expirations; the ability of the Company to successfully execute strategic plans, including restructuring plans; the impact of business combinations and divestitures; manufacturing difficulties or delays, internally or within the supply chain; product efficacy or safety concerns resulting in product recalls or regulatory action; significant adverse litigation or government action, including related to product liability claims; changes to applicable laws and regulations, including tax laws and global health care reforms; trends toward health care cost containment; changes in behavior and spending patterns of purchasers of health care products and services; financial instability of international economies and legal systems and sovereign risk; and increased scrutiny of the health care industry by government agencies. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's most recent Annual Report on Form 10-K, including in the sections captioned 'Cautionary Note Regarding Forward-Looking Statements' and 'Item 1A. Risk Factors,' and in Johnson & Johnson's subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Any forward-looking statement made in this release speaks only as of the date of this release. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.
View source version on businesswire.com:https://www.businesswire.com/news/home/20250414807799/en/
CONTACT: Media contact:
[email protected] contact:
[email protected]
KEYWORD: UNITED STATES NORTH AMERICA NEW JERSEY
INDUSTRY KEYWORD: BIOTECHNOLOGY PHARMACEUTICAL HEALTH CLINICAL TRIALS
SOURCE: Johnson & Johnson
Copyright Business Wire 2025.
PUB: 04/15/2025 06:20 AM/DISC: 04/15/2025 06:20 AM
http://www.businesswire.com/news/home/20250414807799/en
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
3 hours ago
- Business Insider
Lithium Americas Corp. (LAC) Initiated with a Hold at J.P. Morgan
Lithium Americas Corp. (LAC – Research Report) received a Hold rating and price target from J.P. Morgan analyst today. The company's shares closed last Friday at $2.53. Confident Investing Starts Here: The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Lithium Americas Corp. with a $3.85 average price target, representing a 52.17% upside. In a report released on June 19, BMO Capital also reiterated a Hold rating on the stock with a $3.50 price target. Based on Lithium Americas Corp.'s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $22.18 million. In comparison, last year the company had a GAAP net loss of $12.9 million
Business Insider
4 hours ago
- Business Insider
Coterra Energy (CTRA) Receives a Buy from Wells Fargo
Wells Fargo analyst Roger Read maintained a Buy rating on Coterra Energy (CTRA – Research Report) on June 20 and set a price target of $31.00. The company's shares closed last Friday at $26.97. Confident Investing Starts Here: According to TipRanks, Read is a 3-star analyst with an average return of 1.7% and a 53.80% success rate. Read covers the Energy sector, focusing on stocks such as Valero Energy, EOG Resources, and Phillips 66. In addition to Wells Fargo, Coterra Energy also received a Buy from Piper Sandler's Mark Lear in a report issued on June 16. However, on June 9, Morgan Stanley maintained a Hold rating on Coterra Energy (NYSE: CTRA). Based on Coterra Energy's latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $924 million and a net profit of $516 million. In comparison, last year the company earned a revenue of $1.37 billion and had a net profit of $352 million Based on the recent corporate insider activity of 39 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of CTRA in relation to earlier this year. Last month, Stephen Bell, the EVP – Business Development of CTRA sold 100,000.00 shares for a total of $2,525,000.00.
Business Wire
4 hours ago
- Business Wire
2025 Travelers Championship Generates More Than $4 Million for Charity
HARTFORD, Conn.--(BUSINESS WIRE)--The Travelers Companies, Inc. (NYSE: TRV) today announced that the 2025 Travelers Championship – a PGA TOUR Signature Event – generated more than $4 million for over 215 nonprofits, both record highs. Travelers also set a record this year as the longest-running title sponsor in the tournament's history. In the 19 years the company has been title sponsor, the Travelers Championship has generated tens of millions of dollars for charity. Alan Schnitzer, Chairman and Chief Executive Officer of Travelers, said, 'This week truly captured what makes the Travelers Championship so special – world-class golf played before an enthusiastic crowd, all united by a shared purpose. It is a formula that led to a great week of golf and more money raised for charity than ever before. For 19 years, we have been honored to bring the PGA TOUR to Connecticut, and every year I am inspired by the passion of the players, the dedication of our fans and the incredible support from volunteers and partners who rally around our mission to give back. In addition to supporting vital charitable causes, we are proud that the tournament also generates significant economic activity for the state of Connecticut. Congratulations to our 2025 champion, Keegan Bradley, for rising to the top of one of the strongest fields in the game. We are already looking forward to making next year's tournament even more memorable.' The Travelers Championship donates 100% of its net proceeds to nonprofits. This year's primary beneficiary is The Hole in the Wall Gang Camp, an organization based in Ashford, Connecticut, that provides a traditional summer camp experience for children with serious illnesses. Many other worthy charities – spanning arts and culture, education, health care, housing, human services, mental health, food insecurity, science and technology, and youth development – also benefit from their involvement with the Travelers Championship. Andy Bessette, Executive Vice President and Chief Administrative Officer of Travelers, said, 'The Travelers Championship extends far beyond tournament week. We have created a community of fans that spans the region, and it is because of their support that we are able to make such an impact on so many charities, the true winners of the Travelers Championship. We are so grateful to the world's best PGA TOUR players for delivering another tremendous competition that we will all remember for some time.' The 2026 Travelers Championship is scheduled to take place June 22-28 at TPC River Highlands in Cromwell, Connecticut. For more information, visit About Travelers
